Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Silexion Reports $2.5 Million Third-Quarter Net Loss as SIL204 Trial Begins

None

Silexion Therapeutics (NASDAQ: SLXN) reported a net loss of $2.5 million, or $13.70 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported cash and cash equivalents of $4.8 million at quarter-end.

The clinical-stage biotechnology company said the first patient was dosed in its Phase 2/3 SIL204 trial for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center.

  • Third-quarter research and development expense was $1.3 million, down from $2.2 million a year earlier.
  • General and administrative expense was $1.4 million, compared with $1.1 million in the prior-year quarter.
  • Nine-month net loss was $8.8 million, compared with $7.5 million for the first nine months of 2025.
  • During the quarter, Silexion completed a $2.5 million public offering, a $0.84 million warrant inducement transaction and $1.9 million in at-the-market share sales.
  • The company effected a 1-for-24 reverse share split on November 10, 2026.
EARLY ACCESS
Receive SLXNW Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$SLXNW Hedge Fund Activity

We have seen 3 institutional investors add shares of $SLXNW stock to their portfolio, and 2 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles